IMPT-601 is designed to overcome the suppressive tumor microenvironment by enhancing CAR T-cell infiltration, overcoming T-cell exhaustion, and reducing regulatory T-cell numbers through dual ...

SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte ...

EvE Bio, a focused research organization (FRO) supported by Convergent Research and dedicated to systematically mapping the human pharmome - the full network of functional drug?target interactions - ...

Carlsbad, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and ...

Cabaletta Bio Inc. (NASDAQ:CABA) is one of the best stocks under $3 to invest in. On October 27, Cabaletta Bio announced positive clinical data and development updates for its investigational targeted ...

Vor Bio announces a $55.6 million PIPE to fund clinical trials and expects to report updated data in 2025. Vor Bio, a clinical-stage cell and genome engineering company, announced a securities ...

LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited (“Verdiva” or “the Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and ...

Pacibekitug showed statistically significant hs-CRP reduction in CKD patients in the phase 2 TRANQUILITY study, establishing proof-of-concept for IL-6 inhibition. Positive data supports advancing ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cabaletta Bio ( (CABA)) has shared an ...

GRI Bio, Inc. has announced expected interim and topline data readouts from its Phase 2a biomarker study for the lead program GRI-0621, aimed at treating idiopathic pulmonary fibrosis (IPF), in Q2 and ...

South Korea’s ‘National Integrated Bio Big Data Construction Project,’ aimed at fostering innovation in the bio industry and strengthening medical sovereignty, has been progressing sluggishly.

Shares of Tourmaline Bio (NASDAQ:TRML) fell in the premarket on Tuesday after the company posted topline data from a mid-stage trial for its lead candidate, pacibekitug, in patients with elevated high ...